Research programme: quadruple fixed combination HIV therapy - Cipla/DNDi

Drug Profile

Research programme: quadruple fixed combination HIV therapy - Cipla/DNDi

Alternative Names: 4-in-1 fixed combination ARV therapy - Cipla/DNDi; 4-in-1 paediatric antiretroviral drug combination - Cipla/DNDi; Lopinavir/ritonavir/3TC/ABC; Lopinavir/ritonavir/3TC/AZT; Lopinavir/ritonavir/lamivudine/abacavir; Lopinavir/ritonavir/lamivudine/zidovudine; LPV/r/ABC/3TC - Cipla/DNDi; LPV/r/AZT/3TC - Cipla/DNDi

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cipla; Drugs for Neglected Diseases Initiative Foundation
  • Class Dideoxynucleosides; Pyrimidine nucleosides; Pyrimidinones; Thiazoles
  • Mechanism of Action HIV protease inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in HIV-1-infections(In children, In infants, Treatment-naive) in Unknown (PO, Granules)
  • 20 Aug 2012 Early research in HIV-1 infections (Treatment naive, In infants, In children) (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top